Last reviewed · How we verify

NCT05203432

Red Light Intervention on Myopic Progression

Status unknown NA Last updated 12 October 2022
What this trial tests

NA trial testing Red Light Intervention in Myopia in 104 participants. Status unknown.

Timeline
10 February 2022
Primary endpoint
30 June 2024
30 June 2024

Quick facts

Lead sponsorShanghai Eye Disease Prevention and Treatment Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment104
Start date10 February 2022
Primary completion30 June 2024
Estimated completion30 June 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Eye Disease Prevention and Treatment Center — full company profile →

Who can join

Adults 6 to 12, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the effectiveness of using repeated low-level red-light therapy to slow myopia progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Shanghai Eye Disease Prevention and Treatment Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing